The Academy Responds

Image: Anthony Canamucio Although Henry I. Miller is certainly welcome to express his opinions about the risks of biotechnology,1 he should not criticize a detailed report without reading it carefully. Miller indicates that the 2002 National Research Council report2 "invokes a variety of specious arguments." His main example is that the report puts forth "a general assumption that the risks associated with the introduction of genetic novelty are related to the number of genetic changes and th

Written byFred Gould
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Although Henry I. Miller is certainly welcome to express his opinions about the risks of biotechnology,1 he should not criticize a detailed report without reading it carefully. Miller indicates that the 2002 National Research Council report2 "invokes a variety of specious arguments." His main example is that the report puts forth "a general assumption that the risks associated with the introduction of genetic novelty are related to the number of genetic changes and the origin of the novel genes." In fact, the report addresses this assumption in detail and concludes that there is no support for it. The executive summary states, "The committee compared empirical evidence of environmental impacts involving small to large amounts of genetic novelty from taxonomically related and unrelated sources and found no support for this assumption."

Concerning Miller's main point about regulation and logical inconsistencies, we would like to clarify the National Research Council's (NRC) positions. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies